Imulan BioTherapeutics Licenses New Immune Modulator

SCOTTSDALE, Ariz. – (January 7th, 2007)   Imulan BioTherapeutics, LLC (Imulan), a privately-held bioscience company, announced the worldwide licensing of a novel immune modulating vaccine technology for animal health applications. Dr. Craig Woods, CEO of Imulan, stated, “The vaccine proposes to manage a number of conditions, including allergic reactions, infections, cancer and autoimmune disorders. Studies indicate the vaccine helps to restore normal T-helper cell activity and cytokine balance. The potential applications in livestock and companion animals may provide veterinarians a much needed tool to manage a significant number of clinically challenging conditions.“ Founded in 2004, Imulan has initiated the development of several platform technologies, including the ImSAIDs™, for animal health.  Imulan is focused on developing unique immune regulating compounds with predictable effects.  For more information about Imulan, please visit www.imulan.com.

More from

• Animus launches SkinBond Multi for enhanced wound care
• IVC Evidensia reports 82% cut in Farm antibiotic use and 20% carbon emissions reduction
• Vet professionals flock to sign up to transformative locum platform
• The ProSalus Foundation launches urgent appeal for UK vets to support Ukrainian colleagues
• Vetsure Named Business of the Year at 2025 SME National Business Awards